Atai life sciences announces fourth quarter and full year 2021 financial results, reports on r&d progress and highlights strategic focus areas of its innovative mental health platform

–   highlights included positive phase 2b data with comp360 from a ground-breaking treatment resistant depression (trd) trial, highly encouraging phase 2a proof-of-mechanism data with rl-007 in cognitive impairment associated with schizophrenia (cias), clinical trial initiations with pcn-101, grx-917 and dmx-1002, and successful completion of 2 cohorts in the introspect digital therapeutics ketamine trials
ATAI Ratings Summary
ATAI Quant Ranking